Literature DB >> 29404766

Pre-treatment magnetic resonance-based texture features as potential imaging biomarkers for predicting event free survival in anal cancer treated by chemoradiotherapy.

Arnaud Hocquelet1,2,3, Thibaut Auriac4, Cynthia Perier5, Clarisse Dromain6, Marie Meyer7, Jean-Baptiste Pinaquy7, Alban Denys6, Hervé Trillaud4,8, Baudouin Denis De Senneville5, Véronique Vendrely9.   

Abstract

AIM: To assess regular MRI findings and tumour texture features on pre-CRT imaging as potential predictive factors of event-free survival (disease progression or death) after chemoradiotherapy (CRT) for anal squamous cell carcinoma (ASCC) without metastasis.
MATERIALS AND METHODS: We retrospectively included 28 patients treated by CRT for pathologically proven ASCC with a pre-CRT MRI. Texture analysis was carried out with axial T2W images by delineating a 3D region of interest around the entire tumour volume. First-order analysis by quantification of the histogram was carried out. Second-order statistical texture features were derived from the calculation of the grey-level co-occurrence matrix using a distance of 1 (d1), 2 (d2) and 5 (d5) pixels. Prognostic factors were assessed by Cox regression and performance of the model by the Harrell C-index.
RESULTS: Eight tumour progressions led to six tumour-specific deaths. After adjusting for age, gender and tumour grade, skewness (HR = 0.131, 95% CI = 0-0.447, p = 0.005) and cluster shade_d1 (HR = 0.601, 95% CI = 0-0.861, p = 0.027) were associated with event occurrence. The corresponding Harrell C-indices were 0.846, 95% CI = 0.697-0.993, and 0.851, 95% CI = 0.708-0.994.
CONCLUSION: ASCC MR texture analysis provides prognostic factors of event occurrence and requires additional studies to assess its potential in an "individual dose" strategy for ASCC chemoradiation therapy. KEY POINTS: • MR texture features help to identify tumours with high progression risk. • Texture feature maps help to identify intra-tumoral heterogeneity. • Texture features are a better prognostic factor than regular MR findings.

Entities:  

Keywords:  Anal squamous cell carcinoma; Definitive chemoradiotherapy; Imaging biomarkers; Magnetic resonance imaging; Texture analysis

Mesh:

Year:  2018        PMID: 29404766     DOI: 10.1007/s00330-017-5284-z

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  33 in total

1.  Engineering and algorithm design for an image processing Api: a technical report on ITK--the Insight Toolkit.

Authors:  Terry S Yoo; Michael J Ackerman; William E Lorensen; Will Schroeder; Vikram Chalana; Stephen Aylward; Dimitris Metaxas; Ross Whitaker
Journal:  Stud Health Technol Inform       Date:  2002

2.  Anal cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  R Glynne-Jones; P J Nilsson; C Aschele; V Goh; D Peiffert; A Cervantes; D Arnold
Journal:  Ann Oncol       Date:  2014-07-06       Impact factor: 32.976

3.  Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin. UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research.

Authors: 
Journal:  Lancet       Date:  1996-10-19       Impact factor: 79.321

4.  Quantitative analysis and prediction of regional lymph node status in rectal cancer based on computed tomography imaging.

Authors:  Chunyan Cui; Hongmin Cai; Lizhi Liu; Liren Li; Haiying Tian; Li Li
Journal:  Eur Radiol       Date:  2011-06-29       Impact factor: 5.315

5.  Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival.

Authors:  Francesca Ng; Balaji Ganeshan; Robert Kozarski; Kenneth A Miles; Vicky Goh
Journal:  Radiology       Date:  2012-11-14       Impact factor: 11.105

6.  Prognostic impact of tumour burden assessed by metabolic tumour volume on FDG PET/CT in anal canal cancer.

Authors:  Mathieu Gauthé; Marion Richard-Molard; Juliette Fayard; Jean-Louis Alberini; Wulfran Cacheux; Astrid Lièvre
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-08-09       Impact factor: 9.236

7.  Primary esophageal cancer: heterogeneity as potential prognostic biomarker in patients treated with definitive chemotherapy and radiation therapy.

Authors:  Connie Yip; David Landau; Robert Kozarski; Balaji Ganeshan; Robert Thomas; Andriana Michaelidou; Vicky Goh
Journal:  Radiology       Date:  2013-10-28       Impact factor: 11.105

8.  Metabolic tumour volume of anal carcinoma on (18)FDG PET/CT before combined radiochemotherapy is the only independant determinant of recurrence free survival.

Authors:  Siamak Mohammadkhani Shali; Vanessa Schmitt; Florian F Behrendt; Oliver H Winz; Alexander Heinzel; Felix M Mottaghy; Michael J Eble; Frederik A Verburg
Journal:  Eur J Radiol       Date:  2016-05-20       Impact factor: 3.528

Review 9.  Hypoxia imaging and radiotherapy: bridging the resolution gap.

Authors:  David Robert Grimes; Daniel R Warren; Samantha Warren
Journal:  Br J Radiol       Date:  2017-05-25       Impact factor: 3.039

10.  The assessment of local response using magnetic resonance imaging at 3- and 6-month post chemoradiotherapy in patients with anal cancer.

Authors:  Rohit Kochhar; Andrew G Renehan; Damian Mullan; Bipasha Chakrabarty; Mark P Saunders; Bernadette M Carrington
Journal:  Eur Radiol       Date:  2016-04-18       Impact factor: 5.315

View more
  7 in total

1.  Evaluation of renal dysfunction using texture analysis based on DWI, BOLD, and susceptibility-weighted imaging.

Authors:  Jiule Ding; Zhaoyu Xing; Zhenxing Jiang; Hua Zhou; Jia Di; Jie Chen; Jianguo Qiu; Shengnan Yu; Liqiu Zou; Wei Xing
Journal:  Eur Radiol       Date:  2018-12-17       Impact factor: 5.315

Review 2.  [Anal dysplasia and anal cancer].

Authors:  Ulrike Wieland; Frank Oellig; Alexander Kreuter
Journal:  Hautarzt       Date:  2020-04       Impact factor: 0.751

Review 3.  Anal dysplasia and anal cancer. English version.

Authors:  Ulrike Wieland; Frank Oellig; Alexander Kreuter
Journal:  Hautarzt       Date:  2020-12       Impact factor: 0.751

4.  Clinical Practice Guideline: Anal Cancer—Diagnosis, Treatment and Follow-up

Authors:  Robert Siegel; Ricardo Niklas Werner; Stephan Koswig; Matthew Gaskins; Claus Rödel; Felix Aigner
Journal:  Dtsch Arztebl Int       Date:  2021-04-02       Impact factor: 8.251

5.  Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT.

Authors:  P J Brown; J Zhong; R Frood; S Currie; A Gilbert; A L Appelt; D Sebag-Montefiore; A Scarsbrook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-09-04       Impact factor: 9.236

6.  Computed Tomography-Based Radiomics in Predicting T Stage and Length of Esophageal Squamous Cell Carcinoma.

Authors:  Mingwei Yang; Panpan Hu; Minglun Li; Rui Ding; Yichun Wang; Shuhao Pan; Mei Kang; Weihao Kong; Dandan Du; Fan Wang
Journal:  Front Oncol       Date:  2021-10-14       Impact factor: 6.244

7.  Development of a Novel Multiparametric MRI Radiomic Nomogram for Preoperative Evaluation of Early Recurrence in Resectable Pancreatic Cancer.

Authors:  Tian-Yu Tang; Xiang Li; Qi Zhang; Cheng-Xiang Guo; Xiao-Zhen Zhang; Meng-Yi Lao; Yi-Nan Shen; Wen-Bo Xiao; Shi-Hong Ying; Ke Sun; Ri-Sheng Yu; Shun-Liang Gao; Ri-Sheng Que; Wei Chen; Da-Bing Huang; Pei-Pei Pang; Xue-Li Bai; Ting-Bo Liang
Journal:  J Magn Reson Imaging       Date:  2019-12-23       Impact factor: 4.813

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.